In an observational study, anti-PD-L1 immunotherapies were associated with neutropenia, autoimmune hemolytic anemia, and immune thrombocytopenia, as well as others with bicytopenias, showing congruency with the findings of our study, among multiple reports in the literature [11,12]. This evidence concerns the gene CD274 and neutropenia.